ClinicalTrials.gg
RecruitingNCT04910802Updated Sep 16, 2021

Concomitant HPV Vaccination and HPV Screening HPV Infection and Cervical Cancer in Sweden

A Phase 4 interventional study of Gardasil9 in HPV Infection, CIN 2/3 and Cervical Cancer, sponsored by Miriam Elfström. Recruiting at 1 site in Sweden. Open to female participants aged 22 Years to 27 Years. Per ClinicalTrials.gov, last updated 2021-09-16.

Sponsored by Miriam Elfström · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started May 2021; still recruiting 5 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
150,000
Allocation
Not applicable
Ages
22 Years to 27 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections — 10 open to participants now, 20 under way, 8 of them phase 3. Human Papillomavirus Recombinant Vaccine nonavalent · Papillomavirus Infections.

Planned enrollment
Largest of 31
150,000 · median 700
Started
2021
with 3 others
Phase 4
10 of 31
4 open now
Primary completion
2025-12
later than 5 of 19 live
Registered
17th of 31
by date
Lead sponsor
1 of 31
Miriam Elfström

Among the 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections, this one has the largest planned enrollment, is one of 4 that started in 2021, is one of 10 in phase 4, reaches primary completion later than 5 of the 19 other live ones, and was the 17th registered.

Papillomavirus Infections

581 studies on the registry are indexed under Papillomavirus Infections; 133 are open to participants now.

Browse Papillomavirus Infections studies →

Open to participants now

10 of the 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections are open now, in 9 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About Human Papillomavirus Recombinant Vaccine nonavalent

Human Papillomavirus Recombinant Vaccine nonavalent: first FDA approval 2014 (Gardasil 9). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 89 Papillomavirus Infections studies recruiting now, 40 (45%) set no upper age limit and 44 (49%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 22 Years to 27 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections, or all of them as a file.
02

Study summary

The study aims to evaluate whether organised, concomitant HPV vaccination and HPV screening offered to all resident women aged 22-27 will result in a more rapid elimination of HPV infection in Sweden. This objective will be examined at the population level.

Read the detailed description

In Sweden, 150 women die of and 550 women are diagnosed with cervical cancer each year. The average age at diagnosis is about 55 years and every third woman is under 40 years of age. World-wide, there half a million new cases of cervical cancer each year. The underlying cause of cervical cancer is a human papillomavirus (HPV), an infection that can be prevented by vaccination. The first-generation vaccine protects against HPV infection of the two types (16 and 18) that cause to about 70% of all cervical cancer. Since 2015, a second-generation vaccine (Gardasil 9, Sanofi Pasteur MSD SNC) has been available that provides protection against 9 HPV types of which 7 types (16, 18, 31, 33, 35, 45, 52 and 58) cause 90% of all cervical cancer.

In 2016, the World Health Organization (WHO) called on the countries of the world to eliminate cervical cancer as a public health problem. On 17 November 2020, all 194 WHO member states adopted a global strategy to increase the rate of elimination of cervical cancer. The strategy involves three main actions: vaccination, screening, and treatment. In Sweden, girls have been offered school-based vaccination against HPV with Gardasil 4 since 2012. Starting in the autumn of 2020, schoolboys have also been offered vaccination. Since 2019, the second-generation vaccine has been used in the school-based vaccination program. Sweden's vaccination strategy means that the virus will be eliminated among individuals born in 2007 and beyond. It will thus take another 20 years before Sweden can stop the infection in Sweden. Today, the infection continues to spread only among young adults. Studies have shown that vaccination up to age 26 can be effective and within the European Union, 10 out of 29 countries have a so-called catch-up on vaccination program targeting women over the age of 20 but such a catch-up has not been formally introduced in Sweden.

The overall goal is to investigate whether offering women ages 22-26 years vaccination with Gardasil 9 in connection with screening may involve a faster eradication of cervical cancer as a public health problem in Sweden. A regional pilot study will be conducted in 2021 followed by a subsequent scale-up to other regions.

03

Conditions studied

  • HPV Infection
  • CIN 2/3
  • Cervical Cancer
04

Who can participate

Ages eligible
22 Years to 27 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Eligible women will include resident women within the age range of 22-26, who have not opted out of the screening program and who consent to participate in the study.

Women who respond to the invitation and attend screening will be screened with HPV testing by the current routine practise. Women who consent to participate will also be offered HPV vaccination. The HPV vaccine (Gardasil 9) will be offered regardless of whether the woman reports having had prior vaccination with a first-generation vaccine (Gardasil 4) and regardless of screening test result.

Exclusion criteria

Exclusion Criteria:

  1. Known history of severe allergic reaction or to any of the components of the HPV vaccine.For GARDASIL 9: Amorphous aluminium hydroxyphosphate sulphate adjuvant, Sodium chloride, L-histidine, Polysorbate 80 or Sodium borate
  2. Known history of immune-related disorders
  3. Current acute severe febrile illness, except for minor infections such as a cold, mild upper respiratory infection or low-grade fever.
  4. Administration of immunoglobulin or blood-derived products within 6 months prior to scheduled HPV vaccine first dose
  5. Current pregnancy (reported)
  6. Women with a total hysterectomy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150,000 participants (estimated)

Study arms

  • Experimental
    HPV-vaccination

    Women ages 22-26 will be offered concomitant vaccination (1 dose of Gardasil9) and HPV screening. A second dose of Gardasil9 will be administered 3 years later.

    Biological: Gardasil9

Interventions

06

What researchers measure

Primary outcomes

  1. Prevalence of HPV

    Overall and type-specific prevalence of HPV will be obtained from the routine HPV screening programs in the regions that offer HPV screening to this age group.

    Time frame: Measured at recruitment.

  2. Prevalence of HPV

    Overall and type-specific prevalence of HPV will be obtained from the routine HPV screening programs in the regions that offer HPV screening to this age group.

    Time frame: Measured 3 years after recruitment, at the second cervical screening attendance.

  3. Prevalence of HPV

    Overall and type-specific prevalence of HPV will be obtained from the routine HPV screening programs in the regions that offer HPV screening to this age group.

    Time frame: Measure 6 years after recruitment, at the third cervical screening attendance.

Secondary outcomes

  1. Number of women with histopathologically confirmed cervical intraepithelial neoplasia grade 2, 3, or cervical cancer (CIN2+)

    CIN2+ measured through registry linkages, by HPV type in the lesion.

    Time frame: Measured at recruitment, and subsequently at 3 year intervals.

  2. Consumption of resources

    Number of screening and treatment visits.

    Time frame: Measured at recruitment, and subsequently at 3 year intervals.

  3. Number of women with obstetrical complications

    Obstetrical complications such as preterm births measured through registry linkages.

    Time frame: Measured at recruitment, and subsequently at 3 year intervals.

  4. Number of women with cervical specimens found to be benign

    Treatments for cervical abnormalities, measured as excised cervical specimens, found to be benign. Measured through registry linkages.

    Time frame: Measured at recruitment, and subsequently at 3 year intervals.

07

Study locations

1 of 1 sites recruiting
  • Cancer prevention, screening, and counseling unit, Regional Cancer Center of Stockholm-Gotland
    Stockholm, 10239, Sweden
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Documents related to the study can be shared. Data, once collected, will be made available.

Supporting information: Study protocol, Informed consent form

Time frame: The study protocol and informed consent form are available. The SAP will be made available and the analytic code will be available once the first round of results have been analyzed.

Access criteria: Data can be shared with other researchers upon written request. Possibilities to share the data on a digital platform will be investigated.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for Dec 2025, 55 months after the start.

Of 28 phase 4 interventional studies under Papillomavirus Infections, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 92. This study's planned 55 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2021
First posted
Jun 2, 2021
StartActual
May 3, 2021
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2027
Last update
Sep 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04910802
Lead sponsor
Miriam Elfström
Responsible party
Miriam Elfström (Chief development officer, Region Stockholm) — Sponsor-investigator
First posted
Jun 2, 2021
Start date
May 3, 2021
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 16, 2021

Study contacts

Miriam Elfström, PhD
Contact
miriam.elfstrom@sll.se
+46703816277
Helena Andersson, PhD
Contact
helena.t.andersson@sll.se
+46768871126
Joakim Dillner, MD, PhD
study director · Karolinska University Hospital Laboratory

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Papillomavirus Recombinant Vaccine nonavalent

Start the discussion